Browse the corpus

Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was approved by the US Food and Drug Administration (FDA) to help improve glycemic control in adults with type 2 diabetes (T2D) when used alongside diet and exercise. Alogliptin enhances insulin secretion and reduces glucagon levels by prolonging incretin hormone activity. This drug selectively inhibits DPP-4 without affecting DPP-8 or DPP-9, thereby minimizing off-target toxicity. Alogliptin is available as an oral tablet and is administered once daily. Contraindications include hypersensitivity reactions such as anaphylaxis and angioedema. This activity reviews the indications, mechanism of action, contraindications, adverse event profile, administration, toxicity, and relevant drug interactions of alogliptin. This activity provides healthcare professionals with the knowledge and tools necessary for effectively managing T2D and related conditions with alogliptin, as well as for optimizing alogliptin therapy to deliver safe, targeted, and personalized care. This approach enables informed decision-making, allowing healthcare professionals to tailor treatment plans, optimize dosage regimens, and minimize adverse reactions, ultimately improving patient outcomes and advancing care standards. In addition, this activity emphasizes the importance of collaboration within the interprofessional healthcare team, clarifying roles to foster effective teamwork and optimizing patient outcomes. Objectives: Identify appropriate patient populations for alogliptin therapy and ensure it aligns with current clinical guidelines for managing type 2 diabetes. Implement appropriate dosing regimens based on patient-specific factors, including renal function and coexisting conditions, to ensure optimal therapeutic outcomes. Select appropriate complementary therapies and interventions, such as diet and exercise, to enhance the efficacy of alogliptin in managing type 2 diabetes. Collaborate with other healthcare professionals, such as pharmacists and diabetes educators, to optimize alogliptin therapy and address any concerns or adverse events. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose In clinical trials, healthy participants were given doses of up to 800 mg, whereas participants with T2D received doses of 400 mg. No severe adverse effects were observed at these high doses.[32] Management of Overdose In the event of an overdose, clinical monitoring and supportive therapy should be provided. Alogliptin is minimally dialyzable, with only 7% removed during a 3-hour hemodialysis session, making hemodialysis unlikely to be effective. A medical toxicologist or the Poison Control Center should be contacted (at 1-800-222-1222) for current recommendations.

The interprofessional healthcare team members, including physicians, endocrinologists, and advanced practice providers who prescribe alogliptin for T2D, should educate patients on the importance of lifestyle changes, including diet and exercise. Nursing staff, particularly those certified as diabetes educators, are crucial in this aspect of care. Pharmacists should review the regimen, check for potential interactions, assess the appropriateness and synergy of the prescribed agents, and counsel patients on dosing and administration. Both nurses and pharmacists should communicate with the prescribing clinician regarding any concerns or adverse events. A systematic review assessed adherence to newer second-line oral antidiabetic drugs (OADs) marketed between 2012 and 2022, showing better adherence to medications such as alogliptin and SGLT2 inhibitors (61.7%-94.9%) compared to older OADs. However, treatment discontinuation rates were significant (29%-44% within 12 months), emphasizing the need for further studies comparing new and old OADs directly.[33] At the same time, serum glucose, renal function, and baseline liver function tests (as indicated) should also be monitored. Patients should also be monitored for signs and symptoms of heart failure, pancreatitis, and dermatologic or allergic reactions, areas where nursing staff can make a significant contribution. All healthcare providers, including clinicians, pharmacists, and nursing staff, should collaborate and communicate effectively, as well as function as an interprofessional team when a patient receives alogliptin therapy. This approach helps direct the case toward optimal outcomes while minimizing potential adverse events. A systematic review and meta-analysis indicate that interprofessional care for managing T2D in primary care settings enhances patient satisfaction, promotes collaboration among healthcare professionals, and fosters active patient engagement in care. Such collaboration is crucial for improving outcomes and addressing chronic disease management.[34]